Official Master's Degree in AIDS Pathogenesis and Treatment
The Master's Degree in Pathogenesis and Treatment of Aids offers for the first time a wide-ranging vision of immunology and virology, focusing in particular on antiretroviral treatments and eradication methods. It also focuses on other retroviruses and their potential involvement in various human pathologies.
The Universitat Autònoma de Barcelona (UAB) and the Gimbernat School of Nursing and Physiotherapy, through an agreement with the IrsiCaixa Institute for AIDS Research, offer excellent, globally-oriented training in specific skills that will help its graduates to find employment in R+D projects, multidisciplinary teams in the pharmaceutical industry, research groups, technical consultancy on advanced instruments, and adaptation of processes for new techniques.
The discovery of the human immunodeficiency virus (HIV) and its effects on the world population have led to a quantitative and qualitative change in retrovirology research. The advances made in the last 25 years have increased our knowledge of this virus and enabled us to define treatment protocols, as well as laying the foundations for new vaccines and eradication strategies. Thus, human retrovirology has become one of the most dynamic sectors in biomedicine. The strong growth of this research field creates a need for specialists with broad expertise in both virology and immunology.
The programme is structured in seven modules that deal in depth with topics like the cellular and molecular bases of HIV type 1 (HIV-1) infection and associated pathogenesis, fundamental clinical aspects of the infection, emphasising antiretroviral treatment recommendations and resistance to antiretroviral drugs, interactions, similarities and differences between HIV and other related viruses, and the present, past and future of HIV vaccine trials.
In order to reinforce its global orientation, and keep its students up to date on HIV research, the programme includes a module on current lines of research at some of the main research centres in the USA, combining lectures with study visits to these centres. For this reason, the master's degree is delivered in collaboration with the Ragon Institute (MGH, MIT and Harvard) and the Section of Retroviral Therapeutics of the Brigham and Women 's Hospital (Harvard Medical School). It also has the participation of the Leonard M. Miller School of Medicine (University of Miami) and the Center for AIDS Research (University of California, San Diego).
The degree also includes patents in biomedical research so as to highlight the importance of transferring research findings to society. Esteve, a leading international pharmaceutical and healthcare firm, committed to innovation and excellence, has been involved since the beginning in the design and development of this topic within the master's study plan.
Career optionsR+D projects
Multidisciplinary teams in the pharmaceutical industry
Technical consultancy on advanced instruments
Adaptation of processes for new techniques.
Credits: 60 ECTS
Beginning of the pre-enrolment period 23/05/2017
See the calendar
IrsiCaixa Foundation, Germans Trias I Pujol Hospital, Badalona.
Contact us for more information, filling in this form: *Required fields
Once the form has been sent in you will get a confirmation e-mail
Master's degree website http://www.eug.es/estudios/master-universitario-en-patogenesis-y-tratamiento-del-sida/